Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade

With the increasing use of immune checkpoint inhibitors (ICIs) in combination regimens and in earlier stages of advanced melanoma, the effective management of immune-related adverse events (irAEs) is key to balancing immunotherapy efficacy and toxicity. Conflicting evidence exists on possible detrim...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	OncoImmunology
المؤلفون الرئيسيون:	Nina B. Curkovic, Rebecca Irlmeier, Xue Bai, Can Cui, Fei Ye, Hannah R. Burnette, Aleigha R. Lawless, Juliane Andrade Czapla, Ryan Sullivan, Douglas B. Johnson
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Taylor & Francis Group 2025-12-01
الموضوعات:	Immune checkpoint inhibitor immune-related adverse event - irAE immunosuppression immunotherapy
الوصول للمادة أونلاين:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2494433

مواد مشابهة

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
حسب: A.B. Pierre, وآخرون
منشور في: (2023-12-01)

Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action
حسب: Antonio Malvaso, وآخرون
منشور في: (2024-07-01)

Immune-related osteitis mimicking femoral head osteonecrosis during dual checkpoint blockade: a case report
حسب: Enrica Teresa Tanda, وآخرون
منشور في: (2025-10-01)

A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers
حسب: Le Xu, وآخرون
منشور في: (2025-12-01)

Immune Checkpoint Inhibitors and Lupus Erythematosus
حسب: Hans Vitzthum von Eckstaedt, وآخرون
منشور في: (2024-02-01)

Fever of unknown origin associated with immune checkpoint inhibitors
حسب: Xu Tong, وآخرون
منشور في: (2024-03-01)

Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors
حسب: Ping Luo, وآخرون
منشور في: (2025-12-01)

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
حسب: Chiao-En Wu, وآخرون
منشور في: (2020-10-01)

Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
حسب: Yutaka Takahara, وآخرون
منشور في: (2023-09-01)

Enhancing Care Through a Virtual Canadian Community of Practice for Managing Immune-Related Adverse Events
حسب: Khashayar Esfahani, وآخرون
منشور في: (2025-02-01)

Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system
حسب: Chen Li, وآخرون
منشور في: (2025-05-01)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
حسب: Ji Li, وآخرون
منشور في: (2022-05-01)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
حسب: Hiroyuki Ando, وآخرون
منشور في: (2021-10-01)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
حسب: Raju Vaddepally, وآخرون
منشور في: (2022-03-01)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
حسب: Xueyan Wang, وآخرون
منشور في: (2022-10-01)

Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells
حسب: Marianne Gazzano, وآخرون
منشور في: (2022-12-01)

Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
حسب: Carmen Portenkirchner, وآخرون
منشور في: (2021-04-01)

Correlation between thyroid dysfunction and efficacy of immune checkpoint inhibitors in patients with advanced solid tumors
حسب: Cheng Zhao
منشور في: (2024-11-01)

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first
حسب: John A. Storwick, وآخرون
منشور في: (2024-04-01)

Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report
حسب: Ryo Takada, وآخرون
منشور في: (2024-05-01)

A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy
حسب: Yuki Haruta, وآخرون
منشور في: (2024-02-01)

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer
حسب: Ryunosuke Hoshi, وآخرون
منشور في: (2024-09-01)

Case Report: Sudden very late-onset near fatal PD1 inhibitor-associated myocarditis with out-of-hospital cardiac arrest after >2.5 years of pembrolizumab treatment
حسب: Richard I. Lewis, وآخرون
منشور في: (2024-02-01)

Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy—Retrospective Study from a Tertiary-Level Hospital in Romania
حسب: Simona Coniac, وآخرون
منشور في: (2023-05-01)

Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival
حسب: Lisa Yang, وآخرون
منشور في: (2024-04-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
حسب: Xiaoyan Si, وآخرون
منشور في: (2020-02-01)

Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis
حسب: Agnese Paderi, وآخرون
منشور في: (2021-09-01)

Pembrolizumab‐Induced Severe Pneumonitis in a Patient With Lung Adenocarcinoma After Umbilical Cord Blood Transplantation: A Case Report
حسب: Shunta Yamamoto, وآخرون
منشور في: (2025-08-01)

Nail toxicity with nail bed ulceration associated with pembrolizumab
حسب: Shintaro Maeda, وآخرون
منشور في: (2023-12-01)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
حسب: Gunther Glehr, وآخرون
منشور في: (2022-09-01)

Editorial: Hallmark of cancer: tumor promoting inflammation
حسب: Luca Roncati, وآخرون
منشور في: (2023-07-01)

A case of urticarial vasculitis associated with atezolizumab
حسب: Jade N. Young, BS, وآخرون
منشور في: (2024-01-01)

Function of 18F-FDG PET/CT radiomics in the detection of checkpoint inhibitor-induced liver injury (CHILI)
حسب: Clémence M. C. Huigen, وآخرون
منشور في: (2025-08-01)

Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study
حسب: Ge Guo, وآخرون
منشور في: (2024-12-01)

Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review
حسب: Harun Muğlu, وآخرون
منشور في: (2025-02-01)

Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data
حسب: Connor Frey, وآخرون
منشور في: (2024-07-01)

Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
حسب: Sae Ohwada, وآخرون
منشور في: (2022-06-01)

Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
حسب: Ana Cardeña-Gutiérrez, وآخرون
منشور في: (2022-06-01)

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
حسب: Xiaowei Liu, وآخرون
منشور في: (2020-03-01)

Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies
حسب: Qing Zhang, وآخرون
منشور في: (2025-04-01)